D027 E-Portfolio: Advanced Pathopharmacological Foundations
Student Name
Western Governors University
D027 Advanced Pathopharmacological Foundations
Prof. Name
Date
D027 E-Portfolio: Advanced Pathopharmacological Foundations
Instructions
Completion of the Clinical Practice Experience (CPE) Record is a mandatory requirement for this course. You can find the CPE Record under the “Supporting Documents” section in your Assessment Task Overview. This area outlines all necessary deliverables, which must be integrated within your e-portfolio.
Written reflections and submissions can be entered directly into this template. Alternatively, you may embed previously prepared Word or PDF documents by following these steps:
Place the cursor where you want the document inserted.
Select Insert, then click the arrow next to Object.
Choose Text from File.
Locate and double-click the file to embed it.
Repeat this process to insert additional documents as needed.
1a. CPE Schedule Table
This table is intended to help organize your workload and manage your time effectively throughout the Clinical Practice Experience. Please copy this schedule into your e-portfolio and fill in your estimated time commitments and anticipated completion dates.
| Required CPE Activity (Deliverable) | Estimated Time | Anticipated Completion Date |
|---|---|---|
| CPE Schedule Table (Phase 1) | 30 minutes | 08/31/24 |
| Feedback and Synthesis Improvement Plan (Phase 1) | 2 hours | 09/01/24 |
| GoReact Video (Phase 1) | 1 hour | 09/01/24 |
| Peer Responses (Phase 1) | 30 minutes | 09/01/24 |
| Reflection Summary (Phase 1) | 30 minutes | 09/01/24 |
| CPE Schedule Table (Phase 2) | 30 minutes | 09/02/24 |
| Feedback and Synthesis Improvement Plan (Phase 2) | 2 hours | 09/02/24 |
| GoReact Video (Phase 2) | 1 hour | 09/04/24 |
| Peer Responses (Phase 2) | 30 minutes | 09/04/24 |
| Reflection Summary (Phase 2) | 30 minutes | 09/04/24 |
| CPE Schedule Table (Phase 3) | 30 minutes | 09/06/24 |
| Feedback and Synthesis Improvement Plan (Phase 3) | 2 hours | 09/06/24 |
| Feedback and Synthesis Improvement Treatment Plan (Phase 3) | 2 hours | 09/06/24 |
| GoReact Video (Phase 3) | 1 hour | 09/09/24 |
| Peer Responses (Phase 3) | 30 minutes | 09/07/24 |
| Reflection Summary (Phase 3) | 30 minutes | 09/07/24 |
1b. Feedback and Synthesis Improvement Plan
What is Alzheimer’s Disease?
Alzheimer’s disease is a chronic, progressive neurological disorder that irreversibly impairs memory and cognitive function. Initially presenting with mild forgetfulness, it progressively hampers the ability to perform everyday activities. The condition results from widespread neuronal death, causing brain shrinkage and functional decline. According to the Centers for Disease Control and Prevention (CDC), Alzheimer’s is among the top ten causes of death in the U.S. and the leading cause of dementia in older adults (Kumar et al., 2024).
What are the Pathophysiological Features of Alzheimer’s Disease?
Alzheimer’s disease is characterized by two primary pathological markers:
Neuritic Plaques: These are clusters of amyloid beta peptides deposited outside neurons, especially in the brain’s cortical gray matter. These plaques are surrounded by swollen neuronal terminals and disrupt normal brain function.
Neurofibrillary Tangles: These intracellular aggregates consist of abnormally folded tau proteins that normally maintain microtubule stability. In Alzheimer’s, tau proteins misfold and aggregate, impairing intracellular transport and causing neuronal dysfunction. These tangles start in the hippocampus, the brain region responsible for memory, and progressively spread throughout the cerebral cortex (Kumar et al., 2024).
What Are the Clinical Manifestations of Alzheimer’s Disease?
The clinical symptoms evolve in stages:
Early Stage: Patients exhibit memory lapses, difficulty recalling words, spatial confusion, and impaired judgment.
Moderate Stage: Symptoms worsen with increased confusion, changes in personality, disorientation, and behavioral issues.
Severe Stage: There is a loss of independence in self-care, swallowing difficulties, and susceptibility to complications such as aspiration pneumonia, a common cause of death in late-stage Alzheimer’s (National Institute on Aging [NIA], 2022a).
How Is Alzheimer’s Disease Diagnosed?
Diagnosis involves a multi-faceted approach:
Clinical assessment of cognitive function, daily living skills, and behavior.
Neuropsychological testing to evaluate memory, language, attention, and problem-solving abilities.
Laboratory tests, including urinalysis, to rule out alternative causes.
Brain imaging techniques such as CT, MRI, or PET scans to detect brain atrophy and amyloid plaque deposition (NIA, 2022b).
2b. Feedback and Synthesis Improvement Plan
What is Heart Disease?
Heart disease, or cardiovascular disease (CVD), remains the leading cause of death worldwide. It includes various conditions like coronary artery disease, cerebrovascular disease, peripheral artery disease, and aortic atherosclerosis. The core pathological issue is reduced blood flow to the heart muscle, causing ischemia and symptoms such as chest pain (angina) or heart attack (Lopez, 2023).
What Is the Pathophysiology of Heart Disease?
Atherosclerosis is the principal pathological process underlying heart disease. It involves the gradual accumulation of lipids, inflammatory cells, and fibrous tissue within arterial walls. This buildup narrows arteries (stenosis), restricting blood flow. The process begins early in life and is exacerbated by lipid deposits, immune activation, and endothelial dysfunction (Lopez, 2023).
What Are the Clinical Manifestations?
| Symptom | Description |
|---|---|
| Chest Pain | Angina due to decreased myocardial blood flow |
| Shortness of Breath | Resulting from reduced cardiac output |
| Coughing | May suggest pulmonary fluid retention |
| Swelling (Legs, Feet) | Peripheral edema caused by heart failure |
| Fatigue | Reduced oxygen delivery to tissues |
| Palpitations | Irregular heart rhythms or arrhythmias |
How Is Heart Disease Diagnosed?
| Diagnostic Test | Purpose |
|---|---|
| Electrocardiogram (ECG) | Detects arrhythmias and ischemic changes |
| Echocardiogram | Visualizes heart anatomy and function |
| Blood Tests | Measures cardiac enzymes indicating injury |
| Chest X-ray | Assesses heart size and lung congestion |
| Stress Test | Evaluates heart performance under physical exertion |
What Are Common Treatments and Lifestyle Changes?
Management includes medications such as beta-blockers, diuretics, statins, aspirin, and anticoagulants. Lifestyle adjustments are crucial and involve maintaining a balanced diet, engaging in regular exercise, managing stress, maintaining a healthy weight, quitting smoking, and regularly monitoring blood pressure and cholesterol (Lopez, 2023).
3b. Chronic Obstructive Pulmonary Disease (COPD) Synthesis
Patient Case Overview
Ms. O’Connor, 55 years old, presents with worsening COPD symptoms including bronchospasms, fatigue, and productive cough with rusty sputum. Despite nicotine replacement therapies, she continues to smoke 3 to 5 cigarettes daily, a habit dating back to age 15. She has no allergies, spirometry shows an FEV1 of 1.37L, and family history includes a father who died of a heart attack and a mother who passed from smoking-related pneumonia. She has gained 30 pounds in the last two years.
What Is the Pathophysiology of COPD?
COPD develops due to chronic inflammation in the airways caused mainly by prolonged exposure to harmful particles, especially tobacco smoke. This inflammation leads to airway narrowing, destruction of lung elasticity, excessive mucus production, and airflow obstruction. Thickened airway walls cause air trapping and lung hyperinflation, which compromise respiratory function (Agarwal, 2023).
What Are the Signs and Symptoms?
| Sign/Symptom | Description |
|---|---|
| Chronic Cough | Persistent and productive |
| Increased Mucus | Excess sputum secretion |
| Dyspnea | Difficulty breathing |
| Pursed-Lip Breathing | Technique to regulate airflow |
| Wheezing | Audible airway obstruction |
| Muscle Atrophy | Loss of muscle mass due to inactivity |
| Barrel Chest | Enlarged chest diameter from lung hyperinflation |
| Cyanosis | Bluish skin coloration due to hypoxia |
| Finger Clubbing | Nail deformity linked to chronic low oxygen levels |
How Is COPD Diagnosed?
Diagnosis relies on clinical history, spirometry and pulmonary function tests, chest X-rays or CT scans, arterial blood gas analysis, and alpha-1 antitrypsin deficiency screening if indicated (Agarwal, 2023).
What Are Common Treatments?
| Treatment Type | Examples and Purpose |
|---|---|
| Bronchodilators | Short-acting (albuterol) and long-acting (tiotropium) to relax airway muscles |
| Inhaled Corticosteroids | Reduce inflammation in the airways |
| Smoking Cessation Aids | Medications such as bupropion to assist quitting |
| Vaccinations | Annual influenza and pneumococcal vaccines |
| Pulmonary Rehabilitation | Programs to improve exercise tolerance and symptom control |
What Are Possible Side Effects of Medications?
| Medication | Potential Side Effects |
|---|---|
| Bronchodilators | Tremors, anxiety, increased heart rate, headaches |
| Inhaled Corticosteroids | Hoarseness, oral thrush |
| Bupropion | Insomnia, dry mouth, headaches, tremors, sweating |
Reflection Summaries
Phase 1 Reflection
I chose to focus on Alzheimer’s disease due to a personal connection with a family member affected by it. My research deepened my understanding of the key pathological components—amyloid-beta neuritic plaques and tau neurofibrillary tangles. Feedback from an intensivist advised simplifying my synthesis, which improved clarity and comprehension.
Phase 2 Reflection
Heart disease was selected to refresh my clinical knowledge. While researching, balancing the breadth and depth of information proved challenging. Feedback emphasized the need for conciseness and clarity, which I incorporated to enhance the presentation of information.
Phase 3 Reflection
In Phase 3, I worked on the case of Ms. O’Connor with COPD. This interactive task allowed me to develop a comprehensive treatment plan, combining pharmacological and lifestyle interventions. Patient education on medication side effects and adherence was critical. Organizing subjective and objective data while managing documentation constraints was a key challenge.
References
Agarwal, A. K. (2023, August 7). Chronic obstructive pulmonary disease. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK559281/
Kumar, A., Sidhu, J., Lui, F., et al. (2024). Alzheimer Disease. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499922/
Lopez, E. O. (2023, August 22). Cardiovascular disease. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK535419/
National Institute on Aging (NIA). (2022a). What are the signs of Alzheimer’s disease? https://www.nia.nih.gov/health/alzheimerssymptoms-and-diagnosis/what-are-signs-alzheimers-disease
National Institute on Aging (NIA). (2022b, December). How is Alzheimer’s disease diagnosed? https://www.nia.nih.gov/health/alzheimerssymptoms-and-diagnosis/how-alzheimers-disease-diagnosed
American Lung Association. (2024b, May). Understanding your COPD medications. https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treating/copd-medications
Get WGU Free MSN Samples
D024
- D024 SEI Skill Sets Discussion – Self-Awareness & Management Insights
- D024 Phase 1 Video Reflection
- D024 CPE Schedule and SEI Reflection Report
- D024 FAQ: Submission and CPE Record Guidance
- D024 Phase 1 Reflection on Leadership and Growth Strategies
- D024 Joy in the Workplace: Force Field Analysis Summary
- D024 Professional Presence & Influence: CPE Record Template Task 1
D025
- D025 Phase 2 Reflection: Insights on Team Leadership and Advocacy
- D025: Phase 1 Reflection on Health Policy Advocacy Insights
- D025 Task 1: Clinical Practice Experience
- D025 Task 1 ISBAR Summary
- D025 Final Exam: Advocacy for Policy Change in Community Health
- D025 Task 2 Advocating for Policy Change to Improve Health Outcomes in the Community
D026
D027
- D027 Alzheimer’s Disease (AD) Final Synthesis: Understanding Key Aspects
- D027 OA Final Exam Study Guide: Key Concepts and Conditions
- D027 Shadow Health Treatment Plan for Dr. Douglas: Phase 3 Guide
- D027 CCM1 CPE Activity: Phases 1-3 Synthesis & Feedback Summaries
- D027 – Comprehensive Study Guide for Health Disorders and Treatments
- D027 E-Portfolio: Advanced Pathopharmacological Foundations
- D027 Study Guide – Advanced Pathopharmacology Notes
D028
D029
- D029 Narrative Essay: Innovations in Nursing Informatics
- D029 CPE Phase 2
- D029 Emerging Tech Annotated Bibliography for Nursing Care
- D029 Annotated Bibliography
- D029 Population Health Data Paper
- D029 Task 1 E-Portfolio: Clinical Practice Experience Analysis
- D029 Task 1: Analyzing Population Health Data in Strafford Country
D030
D031